Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers. See bulk prices →

Weight loss · Compound

Ozempic Price in the Philippines (2026)

The semaglutide compound page: the molecule in Ozempic, Wegovy and Rybelsus, what its trials measured, what they reported, and what the pens cost in the Philippines.

Philippines Peptides editorial deskUpdated Trial data checked 23 September 202618 min read4 sources

Short answer

As of 23 September 2026, Ozempic 1 mg lists at PHP 9,280 at Rose Pharmacy, Southstar Drug and Watsons. The lowest verified price is PHP 7,599 for the 0.5 mg pen at MedsGo. Mercury Drug publishes no price online. Ozempic is semaglutide from Novo Nordisk, a prescription medicine registered with FDA Philippines, and prescribing belongs with a licensed Philippine physician.

Video guide: Ozempic Price in the Philippines, and the Research Vial (1:53)
Video transcript

Looking up the Ozempic price in the Philippines? Here is what a pen actually costs, checked at Philippine pharmacies in September 2026. Watsons, Southstar Drug and Rose Pharmacy all list the 1 mg pen at ₱9,280. The lowest listing we found was MedsGo, at ₱7,599 for the 0.5 mg pen. Mercury Drug publishes no price online. The label says the 1 mg pen holds 4 doses. That is 4 mg of semaglutide, or about ₱2,320 per mg. Ozempic is registered with FDA Philippines as a prescription medicine. Prescribing belongs with a licensed Philippine physician. Search for semaglutide and you will also find it sold a second way: as a research vial. These are not the same product. The pen is a registered medicine, ready to use. A research vial is not approved for human use, is sold for research only, and comes as a powder you reconstitute. Our partner and supplier, Primara Labs, lists a 15 mg semaglutide vial at ₱1,990, or ₱1,216 per vial in a 10 pack. Side by side, per mg: the pen works out to about ₱2,320. The vial is about ₱133, and about ₱81 in a 10 pack. Every vial order comes with bacteriostatic water, insulin syringes and alcohol pads. Primara stocks in Metro Manila. Orders before noon arrive the same day, provinces ship by J&T, and there is a 60-day money-back guarantee. Read the full price table on Philippines Peptides, then see semaglutide at Primara Labs and order on WhatsApp.

Ozempic price per pen in the Philippines, by strength. Prices checked 23 September 2026.
StrengthRose PharmacySouthstar DrugWatsonsMedsGoMedsGo on Lazada
Ozempic 0.25 mg₱8,187.50₱8,187.50₱8,187.50
Ozempic 0.5 mg₱8,187.50₱8,187.50₱8,187.50₱7,599₱8,950.45
Ozempic 1 mg₱9,280₱9,280₱9,280

Price per 1 pen, as each pharmacy or clinic lists it on its own page, checked 23 September 2026. An empty cell means that seller publishes no price for that strength online; nothing is estimated. Mercury Drug publishes no prices online.

Wegovy is the same molecule, semaglutide, at weight-management strengths, and has its own per-pen table: Wegovy price Philippines. Both are prescription medicines, and prescribing belongs with a licensed Philippine physician.

Body weight fell on the 2.4 mg arm in STEP 1, a 68-week phase 3 trial of 1,961 adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes, against 2.4% on placebo
14.9%
Completed trials with a reported result in the Research Desk dataset
6

The strongest evidence found for Semaglutide comes from phase 3 human trials, and every finding below carries its evidence level.

What is Semaglutide

Semaglutide is a GLP-1 analogue made by Novo Nordisk. It is the active ingredient in Ozempic (a weekly injection registered for type 2 diabetes), Wegovy (a weekly injection registered for weight management) and Rybelsus (a daily tablet). All three are prescription medicines in the Philippines.

The pens and tablets are registered medicines, made and released under a regulator-approved process. A research-grade vial of semaglutide is not a medicine, is not registered anywhere, and is not a substitute for a prescribed pen.

How it works

Semaglutide binds to and activates the GLP-1 receptor, the same receptor the body’s own GLP-1 hormone uses. That receptor sits in the pancreas, the gut and the brain, which is why the trials measured effects on blood sugar, appetite and body weight.

The molecule carries a fatty-acid side chain that binds albumin in the blood, which is what gives it a half-life long enough for once-weekly injection in the branded pens.

Tirzepatide and retatrutide add further receptors (GIP, and GIP plus glucagon). The tirzepatide and retatrutide guides cover their trials. Other research compounds sit far behind that trial record: MOTS-c Philippines is rated animal and cell in the evidence dataset, and NAD+ Philippines is rated small human studies. The two registered pens are compared directly on Mounjaro vs Ozempic, and pharmacy-prepared versions are explained in the compounded tirzepatide guide.

Registration in the Philippines

Ozempic is registered with FDA Philippines as a prescription drug. The verification portal returned these certificate of product registration numbers on 23 September 2026:

  • BR-1346: Ozempic, 0.25 mg/0.19 mL (1.34 mg/mL)
  • BR-1328: Ozempic, 0.25 mg/0.19 mL (1.34 mg/mL)
  • BR-1327: Ozempic, 0.5 mg/0.37 mL (1.34 mg/mL)
  • BR-1326: Ozempic, 1 mg/0.74 mL (1.34 mg/mL)

Ozempic 2 mg: No Philippine registration identified. No Ozempic 2 mg row: no Philippine registration for an Ozempic 2 mg pen was identified.

Check any registration yourself on the FDA Philippines verification portal.

Wegovy is registered with FDA Philippines as a prescription drug. The verification portal returned these certificate of product registration numbers on 23 September 2026:

  • BR-1468: Wegovy, 0.25 mg/0.37 mL (0.68 mg/mL)
  • BR-1470: Wegovy, 0.5 mg/0.37 mL (1.34 mg/mL)
  • BR-1471: Wegovy, 1 mg/0.75 mL (1.34 mg/mL)
  • BR-1472: Wegovy, 1.7 mg/0.75 mL (2.27 mg/mL)
  • BR-1469: Wegovy, 2.4 mg/0.75 mL (3.2 mg/mL)
  • BR-1477: Wegovy, 0.25 mg/0.5 mL (0.5 mg/mL)
  • BR-1476: Wegovy, 0.5 mg/0.5 mL (1 mg/mL)
  • BR-1475: Wegovy, 1 mg/0.5 mL (2 mg/mL)
  • BR-1474: Wegovy, 1.7 mg/0.75 mL (2.27 mg/mL)
  • BR-1473: Wegovy, 2.4 mg/0.75 mL (3.2 mg/mL)

Wegovy tablets: No Philippine registration identified. No oral Wegovy row in the register search.

Check any registration yourself on the FDA Philippines verification portal.

Benefits studied

  • Body-weight reduction

    Phase 3 human

    STEP 1, a phase 3 trial of 1,961 adults with obesity or overweight and no diabetes, recorded an average 14.9% fall in body weight on the 2.4 mg arm over 68 weeks, against 2.4% on placebo. Source: Wilding JPH et al. N Engl J Med 2021;384:989-1002

  • Cardiovascular events

    Phase 3 human

    SELECT, a phase 3 outcomes trial of 17,604 people aged 45 or over with cardiovascular disease, excess weight and no diabetes, found cardiovascular death, heart attack or stroke in 6.5% on semaglutide against 8.0% on placebo (hazard ratio 0.80). Source: Lincoff AM et al. N Engl J Med 2023 (SELECT)

  • Body-weight reduction with type 2 diabetes

    Phase 3 human

    STEP 2 (phase 3, 1,210 adults with type 2 diabetes and a BMI of at least 27) recorded an average 9.6% weight loss on 2.4 mg over 68 weeks, against 3.4% on placebo. Source: Davies M et al. Lancet 2021 (STEP 2)

  • Two-year weight reduction

    Phase 3 human

    STEP 5, a two-year phase 3 trial of 304 adults with obesity or overweight and no diabetes, found an average 15.2% weight loss on 2.4 mg at 104 weeks, against 2.6% on placebo. Source: Garvey WT et al. Nat Med 2022 (STEP 5)

  • Maintenance of weight reduction

    Phase 3 human

    STEP 4, a phase 3 withdrawal trial of 803 people, found that those who stayed on semaglutide after a 20-week run-in lost a further 7.9% by week 68, while those moved to placebo regained 6.9%. Source: Rubino D et al. JAMA 2021 (STEP 4)

Side effects reported

STEP 2, a 68-week phase 3 trial of 1,210 adults with BMI of at least 27 kg/m2 and HbA1c 7-10% (53-86 mmol/mol), diagnosed with type 2 diabetes at least 180 days before screening, reported:

Adverse events in STEP 2, share of participants
Adverse event2.4 mg1.0 mgPlacebo
Gastrointestinal adverse events63.5%57.5%34.3%

Source

The same figures as sentences
  • Gastrointestinal adverse events: 63.5% and 57.5% on the 2.4 and 1.0 mg arms, against 34.3% on placebo.
Adverse events in STEP 3, STEP 4, STEP 5, STEP 8 and SELECT

STEP 3, a 68-week phase 3 trial of 611 participants (uS adults without diabetes with overweight (BMI 27 or greater) plus at least 1 comorbidity or obesity (BMI 30 or greater)), reported:

Adverse events in STEP 3, share of participants
Adverse event2.4 mgPlacebo
Discontinuation for adverse events5.9%2.9%
Gastrointestinal adverse events82.8%63.2%
Nausea58.2%22.1%
Constipation36.9%24.5%
Diarrhoea36.1%22.1%
Vomiting27.3%10.8%

Source

The same figures as sentences
  • Discontinuation for adverse events: 5.9% on the 2.4 mg arm, against 2.9% on placebo.
  • Gastrointestinal adverse events: 82.8% on the 2.4 mg arm, against 63.2% on placebo.
  • Nausea: 58.2% on the 2.4 mg arm, against 22.1% on placebo.
  • Constipation: 36.9% on the 2.4 mg arm, against 24.5% on placebo.
  • Diarrhoea: 36.1% on the 2.4 mg arm, against 22.1% on placebo.
  • Vomiting: 27.3% on the 2.4 mg arm, against 10.8% on placebo.

STEP 4, a 68-week phase 3 trial of 803 adults with BMI of at least 30 (or 27 or greater with at least 1 weight-related comorbidity) without diabetes, who reached the 2.4 mg maintenance dose during a 20-week run-in, reported:

Adverse events in STEP 4, share of participants
Adverse eventContinued 2.4 mg, weeks 20 to 68Switched to placebo
Discontinuation for adverse events2.4%2.2%
Gastrointestinal adverse events41.9%26.1%
Diarrhoea14.4%7.1%
Nausea14%4.9%
Constipation11.6%6.3%
Vomiting10.3%3%

Source

The same figures as sentences
  • Discontinuation for adverse events: 2.4% on the Continued 2.4 mg, weeks 20 to 68 arm, against 2.2% on switched to placebo.
  • Gastrointestinal adverse events: 41.9% on the Continued 2.4 mg, weeks 20 to 68 arm, against 26.1% on switched to placebo.
  • Diarrhoea: 14.4% on the Continued 2.4 mg, weeks 20 to 68 arm, against 7.1% on switched to placebo.
  • Nausea: 14% on the Continued 2.4 mg, weeks 20 to 68 arm, against 4.9% on switched to placebo.
  • Constipation: 11.6% on the Continued 2.4 mg, weeks 20 to 68 arm, against 6.3% on switched to placebo.
  • Vomiting: 10.3% on the Continued 2.4 mg, weeks 20 to 68 arm, against 3% on switched to placebo.

STEP 5, a 104-week phase 3 trial of 304 adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, reported:

Adverse events in STEP 5, share of participants
Adverse event2.4 mgPlacebo
Discontinuation for adverse events5.9%4.6%
Gastrointestinal adverse events82.2%53.9%
Nausea53.3%21.7%
Diarrhoea34.9%23.7%
Constipation30.9%11.2%
Vomiting30.3%4.6%

Source

The same figures as sentences
  • Discontinuation for adverse events: 5.9% on the 2.4 mg arm, against 4.6% on placebo.
  • Gastrointestinal adverse events: 82.2% on the 2.4 mg arm, against 53.9% on placebo.
  • Nausea: 53.3% on the 2.4 mg arm, against 21.7% on placebo.
  • Diarrhoea: 34.9% on the 2.4 mg arm, against 23.7% on placebo.
  • Constipation: 30.9% on the 2.4 mg arm, against 11.2% on placebo.
  • Vomiting: 30.3% on the 2.4 mg arm, against 4.6% on placebo.

STEP 8, a 68-week phase 3b trial of 338 participants (uS adults with BMI of 30 or greater, or 27 or greater with 1 or more weight-related comorbidities, without diabetes), reported:

Adverse events in STEP 8, share of participants
Adverse eventSemaglutide 2.4 mgLiraglutide 3.0 mgPlacebo (pooled)
Discontinuation for adverse events3.2%12.6%3.5%
Gastrointestinal disorders84.1%82.7%55.3%
Nausea61.1%59.1%22.4%
Constipation38.9%31.5%23.5%
Diarrhoea27.8%18.1%25.9%
Vomiting25.4%20.5%5.9%

Source

The same figures as sentences
  • Discontinuation for adverse events: 3.2% and 12.6% on the Semaglutide 2.4 and Liraglutide 3.0 mg arms, against 3.5% on placebo (pooled).
  • Gastrointestinal disorders: 84.1% and 82.7% on the Semaglutide 2.4 and Liraglutide 3.0 mg arms, against 55.3% on placebo (pooled).
  • Nausea: 61.1% and 59.1% on the Semaglutide 2.4 and Liraglutide 3.0 mg arms, against 22.4% on placebo (pooled).
  • Constipation: 38.9% and 31.5% on the Semaglutide 2.4 and Liraglutide 3.0 mg arms, against 23.5% on placebo (pooled).
  • Diarrhoea: 27.8% and 18.1% on the Semaglutide 2.4 and Liraglutide 3.0 mg arms, against 25.9% on placebo (pooled).
  • Vomiting: 25.4% and 20.5% on the Semaglutide 2.4 and Liraglutide 3.0 mg arms, against 5.9% on placebo (pooled).

SELECT, a phase 3 trial of 17,604 participants (patients 45 years or older with preexisting cardiovascular disease and BMI of 27 or greater, no history of diabetes), reported:

Adverse events in SELECT, share of participants
Adverse eventSemaglutide 2.4 mgPlacebo
Discontinuation for adverse events16.6%8.2%

Source

The same figures as sentences
  • Discontinuation for adverse events: 16.6% on the Semaglutide 2.4 mg arm, against 8.2% on placebo.

What the trials found

In STEP 1, a 68-week phase 3 trial of 1,961 adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes, body weight fell by 14.9% on the 2.4 mg arm, against 2.4% on placebo. Source · Registry

Completed trials of Semaglutide with a reported result. Outcome: body weight
Trial and populationnWeeksChange by armComparatorSource
STEP 1 · Phase 3Adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes1,961682.4 mg −14.9%Placebo −2.4%Source · Registry
STEP 2 · Phase 3Adults with BMI of at least 27 kg/m2 and HbA1c 7-10% (53-86 mmol/mol), diagnosed with type 2 diabetes at least 180 days before screening1,210682.4 mg −9.6%Placebo −3.4%Source · Registry
STEP 3 · Phase 3US adults without diabetes with overweight (BMI 27 or greater) plus at least 1 comorbidity or obesity (BMI 30 or greater)611682.4 mg −16%Placebo −5.7%Source · Registry
STEP 4 · Phase 3Adults with BMI of at least 30 (or 27 or greater with at least 1 weight-related comorbidity) without diabetes, who reached the 2.4 mg maintenance dose during a 20-week run-in80368Continued 2.4 mg, weeks 20 to 68 −7.9%Switched to placebo 6.9%Source · Registry
STEP 5 · Phase 3Adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes3041042.4 mg −15.2%Placebo −2.6%Source · Registry
STEP 8 · Phase 3bUS adults with BMI of 30 or greater, or 27 or greater with 1 or more weight-related comorbidities, without diabetes33868Semaglutide 2.4 mg −15.8%Liraglutide 3.0 mg −6.4%Placebo (pooled) −1.9%Source · Registry
Body weight change on the highest-dose arm against placebo, Semaglutide trials
Body weight change on the highest-dose arm against placebo, Semaglutide trials
TrialHighest-dose armComparator
STEP 12.4 mg −14.9%Placebo −2.4%
STEP 22.4 mg −9.6%Placebo −3.4%
STEP 32.4 mg −16%Placebo −5.7%
STEP 4Continued 2.4 mg, weeks 20 to 68 −7.9%Switched to placebo 6.9%
STEP 52.4 mg −15.2%Placebo −2.6%
STEP 8Liraglutide 3.0 mg −6.4%Placebo (pooled) −1.9%

Each pair is one trial: the highest-dose arm (dark) and the comparator (light). Full results and arms are in the table above.

The same figures as sentences
  • In STEP 2, a 68-week phase 3 trial of 1,210 adults with BMI of at least 27 kg/m2 and HbA1c 7-10% (53-86 mmol/mol), diagnosed with type 2 diabetes at least 180 days before screening, body weight fell by 9.6% on the 2.4 mg arm, against 3.4% on placebo. Source · Registry
  • In STEP 3, a 68-week phase 3 trial of 611 participants (uS adults without diabetes with overweight (BMI 27 or greater) plus at least 1 comorbidity or obesity (BMI 30 or greater)), body weight fell by 16% on the 2.4 mg arm, against 5.7% on placebo. Source · Registry
  • In STEP 4, a 68-week phase 3 trial of 803 adults with BMI of at least 30 (or 27 or greater with at least 1 weight-related comorbidity) without diabetes, who reached the 2.4 mg maintenance dose during a 20-week run-in, body weight changed by -7.9% on the Continued 2.4 mg, weeks 20 to 68 arm, against 6.9% on switched to placebo. Source · Registry
  • In STEP 5, a 104-week phase 3 trial of 304 adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, body weight fell by 15.2% on the 2.4 mg arm, against 2.6% on placebo. Source · Registry
  • In STEP 8, a 68-week phase 3b trial of 338 participants (uS adults with BMI of 30 or greater, or 27 or greater with 1 or more weight-related comorbidities, without diabetes), body weight fell by 15.8% and 6.4% on the Semaglutide 2.4 mg and Liraglutide 3.0 mg arms, against 1.9% on placebo (pooled). Source · Registry

Regulatory status

FDA Philippines
Registered only as branded prescription medicines: Ozempic, Wegovy and Rybelsus (17 certificates of product registration).
US FDA
Approved for glycemic control in type 2 diabetes mellitus and related cardiovascular and kidney risk reduction (Ozempic, Rybelsus); chronic weight management and cardiovascular risk reduction in obesity or overweight (Wegovy).Drugs@FDA: Ozempic (NDA209637, approved 5 December 2017); WEGOVY (injection) (NDA215256, approved 4 June 2021); RYBELSUS / OZEMPIC (tablets) (NDA213051, approved 20 September 2019); Rybelsus (NDA213182, approved 16 January 2020); WEGOVY (tablets) (NDA218316, approved 22 December 2025). The approval covers the named branded medicine for its labelled use only, never a vial of the same substance sold for research use.
European Medicines Agency
Approved for type 2 diabetes mellitus (Ozempic, Rybelsus), weight management (Wegovy) and non-cirrhotic MASH with F2 to F3 fibrosis (Kayshild).Five authorised products containing semaglutide, all held by Novo Nordisk A/S. The authorisation covers the named medicines only.
Next milestone
None sought: an approved medicine already exists.

Checked 23 September 2026. Primary source

How Philippine registration and prescription rules work, and what an unregistered product is under the law, is covered in the regulation hub, and every compound's status side by side is on the status page. This is general information, not legal advice.

Who should not use Semaglutide

FAQ

How much is Ozempic in the Philippines?

As of 23 September 2026, Ozempic 1 mg lists at PHP 9,280 at Rose Pharmacy, Southstar Drug and Watsons. The lowest verified price is PHP 7,599 for the 0.5 mg pen at MedsGo.

How much is Wegovy in the Philippines?

As of 23 September 2026, Wegovy 2.4 mg lists at PHP 12,650 at Rose Pharmacy, Southstar Drug and Watsons. The lowest verified price is PHP 9,890 for the 1 mg pen at MedsGo.

How much is Ozempic at Mercury Drug?

Mercury Drug publishes no medicine prices online; its Order Online page is a phone form, so its Ozempic price has to be asked in store or by phone. Every published Philippine price is on the Ozempic price page, with the pharmacy page it was read from.

Is semaglutide registered with FDA Philippines?

Yes, as branded medicines. The FDA Philippines verification portal lists Ozempic (BR-1346, BR-1328, BR-1327, BR-1326) and Wegovy (BR-1468, BR-1470, BR-1471, BR-1472, BR-1469, BR-1477, BR-1476, BR-1475, BR-1474, BR-1473) as prescription drugs, checked 23 September 2026. A research-grade vial of semaglutide is not a registered medicine.

Do you need a prescription for Ozempic or Wegovy in the Philippines?

Yes. Both are prescription medicines in the Philippines, and prescribing belongs with a licensed Philippine physician.

What is the cheapest Ozempic or Wegovy price in the Philippines?

On 23 September 2026 the lowest verified Ozempic price was PHP 7,599 for the 0.5 mg pen at MedsGo, and the lowest Wegovy price PHP 9,890 for the 1 mg pen at MedsGo.

Where to get Semaglutide in the Philippines

Branded Ozempic and Wegovy are dispensed by licensed pharmacies against a prescription; current prices by pharmacy are in the price tracker. The supply index covers what to ask any seller before paying.

GLP-1 price trackerSupply index

Primary sources

Citations supporting the clinical claims on this page. Each entry links to the primary record.

All 4 sources: STEP 1 Trial: semaglutide 2.4mg for obesity, SELECT: CV events in non-diabetic obesity, Ozempic prescribing information, US FDA and more

  1. STEP 1 Trial: semaglutide 2.4mg for obesityTrial

    Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med 2021;384:989-1002.

    DOI: 10.1056/NEJMoa2032183

  2. SELECT: CV events in non-diabetic obesityTrial

    Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med 2023;389:2221-2232.

    DOI: 10.1056/NEJMoa2307563

  3. Ozempic prescribing information, US FDALabel

    Novo Nordisk. Ozempic (semaglutide) injection prescribing information. US FDA-approved label.

    Source

  4. GLP-1 receptor agonist mechanism reviewMechanism

    Drucker DJ. "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." Cell Metabolism 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

Editorial Status
Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
November 3, 2026

Related peptides

Related guides

Updated